INTRODUCTION Drug discovery for central nervous system (CNS) disorders has been challenged with markedly high attrition rate.This has driven extensive preclinical and clinical CNS pharmacokinetic (PK) and pharmacodynamic evaluation recently.In clinical programs, human cerebrospinal fluid (CSF) sampling and positron emission tomography (PET) studies have become "routine" but at high cost.